Released Mar 17, 2021, after the close
10-Q filed Mar 17, 2021, 45 days after period end · 0001654954-21-002934
Q1 2021 · 10-Q
Revenue$4.49M$4.49M −2.7% vs Q1 2020−10.7% vs Q4 2020
Net Income$268.03K$268.03K −49.1% vs Q1 2020+85.7% vs Q4 2020
EPS, diluted—
Gross Profit$1,315,110−17.1%
Operating Income$319,121−40.5%
Operating Cash Flow$588,186−61.2%
Free Cash Flowderived$585,618−61.1%
Margins · derived
Gross margin29.3%−5.1 pt vs Q1 2020
Operating margin7.1%−4.5 pt vs Q1 2020
Net margin6.0%−5.4 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $4.49M | $4.61M | $4.57M | $3.73M |
| Net Income | $268.03K | $526.90K | $471.02K | -$2.66M |
| EPS Diluted | — | — | — | -$0.12 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR